Raleigh Capital Management’s Ionis Pharmaceuticals IONS Stock Holding History

Raleigh Capital Management’s Portfolio IONS Stock Details IONS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-72	Closed	-$2.52K	–	793
2024 Q4	$2.52K	Hold	72	–	–	﹤0.01%	811
2024 Q3	$2.88K	Hold	72	–	–	﹤0.01%	777
2024 Q2	$3.43K	Hold	72	–	–	﹤0.01%	719
2024 Q1	$3.12K	Hold	72	–	–	﹤0.01%	717
2023 Q4	$3.64K	Hold	72	–	–	﹤0.01%	798
2023 Q3	$3.27K	Hold	72	–	–	﹤0.01%	742
2023 Q2	$2.95K	Hold	72	–	–	﹤0.01%	710
2023 Q1	$2.57K	Sell	72 -72	-50%	-$2.7K	﹤0.01%	740
2022 Q4	$5.44K	Buy	144 +72	+100%	+$3.03K	﹤0.01%	537
2022 Q3	$3K	Hold	72	–	–	﹤0.01%	592
2022 Q2	$3K	Hold	72	–	–	﹤0.01%	508
2022 Q1	$3K	Buy	+72	New	+$2.36K	﹤0.01%	516

Other funds holding IONS

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Raleigh Capital Management's IONS Position: Q1 2025 in Review

Raleigh Capital Management sold out of Ionis Pharmaceuticals (IONS) in Q1 2025, closing a stake of 72 shares — an estimated $2.52K sold.

Raleigh Capital Management first reported a position in IONS in Q1 2022 and held it in 12 quarters. The position peaked at $5.44K in Q4 2022. 343 funds tracked by Wall St. Rank hold IONS as of Q1 2025.

Raleigh Capital Management reported no remaining Ionis Pharmaceuticals position as of Q1 2025 after selling out during the quarter.
Raleigh Capital Management sold 72 Ionis Pharmaceuticals shares in Q1 2025, an estimated $2.52K.
Raleigh Capital Management first reported a position in Ionis Pharmaceuticals in Q1 2022 and held it in 12 quarters.
Raleigh Capital Management's Ionis Pharmaceuticals position peaked at $5.44K in Q4 2022.
343 funds tracked by Wall St. Rank held Ionis Pharmaceuticals as of Q1 2025.

Based on Raleigh Capital Management's 13F filing for Q1 2025, filed 29 Apr 2025.